BioLife Solutions director granted 8,170 shares

Ellingson Rachel reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Ellingson Rachel reported acquisition or exercise transactions in this Form 4 filing.

BioLife Solutions Inc. director Rachel Ellingson reported receiving a grant of 8,170 shares of restricted common stock. The award was recorded at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.

These shares were granted under the BioLife Solutions 2023 Performance Incentive Plan and, according to the terms, fully vest on the first anniversary of the vesting date of January 2, 2026. Following this grant, Ellingson directly holds a total of 57,995 shares of BioLife Solutions common stock.

Insider Trade Summary

Grant/Award: 8,170 shares

Grant/Award 1 txn

Insider Ellingson Rachel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,170	$0.00	$0.00

Holdings After Transaction: Common Stock — 57,995 shares (Direct)

Footnotes (1)

1. F1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioLife Solutions (BLFS) report for Rachel Ellingson?

BioLife Solutions reported that director Rachel Ellingson received a grant of 8,170 shares of restricted common stock. The grant was recorded at $0.00 per share and represents stock-based compensation awarded under the company’s 2023 Performance Incentive Plan, not an open-market share purchase.

How many BioLife Solutions (BLFS) shares does Rachel Ellingson hold after this Form 4?

After the reported grant, Rachel Ellingson directly holds 57,995 shares of BioLife Solutions common stock. This total reflects the addition of 8,170 restricted shares granted to her, as disclosed in the Form 4 insider transaction filing with the Securities and Exchange Commission.

What are the vesting terms of the restricted stock granted to the BioLife Solutions (BLFS) director?

The restricted stock granted to director Rachel Ellingson fully vests on the first anniversary of the vesting date of January 2, 2026. This schedule, disclosed in the Form 4 footnote, means the grant becomes fully earned according to the company’s 2023 Performance Incentive Plan.

Was the BioLife Solutions (BLFS) restricted stock grant to Rachel Ellingson a market purchase?

No, the transaction was a grant of restricted common stock recorded at $0.00 per share. It represents stock-based compensation awarded under the BioLife Solutions 2023 Performance Incentive Plan, rather than an open-market buy or sell transaction executed at prevailing market prices.

What plan governed the restricted stock award reported for BioLife Solutions (BLFS)?

The restricted stock award to director Rachel Ellingson was granted under the BioLife Solutions 2023 Performance Incentive Plan. This plan provides for equity-based compensation, and the Form 4 notes that the shares fully vest on the first anniversary of the vesting date of January 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 05:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ellingson Rachel

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		8,170	A	(1)	57,995	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026

Remarks:

	/s/ Rachel Ellingson	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.